Dogwood Therapeutics Inc (DWTX) USD0.0001

Sell:$4.90Buy:$5.24$0.09 (1.80%)

Prices delayed by at least 15 minutes
Sell:$4.90
Buy:$5.24
Change:$0.09 (1.80%)
Prices delayed by at least 15 minutes
Sell:$4.90
Buy:$5.24
Change:$0.09 (1.80%)
Prices delayed by at least 15 minutes

Company Information

About this company

Dogwood Therapeutics, Inc., formerly Virios Therapeutics, Inc., is focused on the clinical development of three assets, Halneuron, IMC-1, and IMC-2. Halneuron is in Phase 2b development as a non-opioid, Nav 1.7 inhibitor, to treat the neuropathic pain associated with chemotherapy treatment. Halneuron is an injectable formulation of Tetrodotoxin, a novel small molecule with action exclusively on the peripheral nervous system. IMC-2 (valacyclovir + celecoxib) is in Phase 2 development as a combination antiviral treatment for Long-COVID (LC). IMC-1 (famciclovir (FM) + celecoxib) is Phase 3 development ready as a combination antiviral treatment for FM. IMC-1 has been granted fast track designation by the FDA. IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms.

Key people

Gregory Scott Duncan
Chairman of the Board, Chief Executive Officer
Angela Walsh
Chief Financial Officer
Ralph Grosswald
Senior Vice President - Operations
R. Michael Gendreau
Chief Medical Officer
Melvin Toh
Director
Alan Yu
Director
Abel De La Rosa
Independent Director
David Keefer
Independent Director
John C. Thomas
Independent Director
Click to see more

Key facts

  • EPIC
    DWTX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US92829J2033
  • Market cap
    $10.78m
  • Employees
    4
  • Shares in issue
    1.92m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.